FDA panel considers loosening regulations on certain unapproved peptides
Summary
The Food and Drug Administration (FDA) advisory panel met to discuss easing rules on some peptide drugs that are not yet officially approved. On Thursday, the panel voted to allow more access to four specific peptides.Key Facts
- The FDA advisory panel is reviewing rules on unapproved peptide drugs.
- The meeting lasted for two days.
- On Thursday, the panel voted to expand access to four peptides.
- Peptides are small chains of amino acids used in medicines and supplements.
- These peptides currently have restrictions because they are not fully approved by the FDA.
- The change would let more patients or doctors use these peptides under looser regulations.
- The FDA panel advises but does not make the final decision.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
